Cixutumumab and Temsirolimus Phase I Trial Aims to Determine Optimal Dose and Safety in Advanced Cancer

Patients with locally advanced or metastatic cancer often face limited treatment options, necessitating the development of novel therapeutic strategies. Traditional chemotherapy regimens frequently encounter resistance or unacceptable toxicity, highlighting the need for targeted approaches. The insulin-like growth factor-1 receptor (IGF-1R) pathway is implicated in cancer cell proliferation, survival, and metastasis, making it an attractive therapeutic target. Similarly, the mammalian target of rapamycin (mTOR) pathway, a critical regulator of cell growth and metabolism, is often dysregulated in various cancers. Combining agents that target these distinct yet interconnected pathways, such as the anti-IGF-1R monoclonal antibody cixutumumab and the mTOR inhibitor temsirolimus, offers a rational strategy to potentially overcome resistance and enhance anti-tumor effects.

This Phase I clinical trial was designed to evaluate the safety profile and determine the maximum tolerated dose (MTD) of cixutumumab when administered in combination with temsirolimus. The study enrolled patients diagnosed with locally advanced or metastatic cancer. The primary objectives included assessing dose-limiting toxicities (DLTs) and characterizing the pharmacokinetic profile of the combination therapy. The trial aimed to establish a safe and biologically active dose regimen for future Phase II efficacy studies. Specific dosing schedules, routes of administration, and patient numbers (n) are not detailed in the provided abstract, which focuses on the study's overarching purpose.

This Phase I study was primarily designed to identify the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLTs) of cixutumumab in combination with temsirolimus in patients with locally advanced or metastatic cancer. The abstract describes the objective to determine the side effects and best dose of this combination, rather than reporting specific results from the trial itself. It aimed to establish a safe and tolerable dosing regimen for future efficacy studies. The rationale for combining these agents stems from their distinct mechanisms: cixutumumab targets the IGF-1R to block cancer cell growth and spread, while temsirolimus inhibits mTOR to disrupt enzymes essential for cell proliferation. The study's design was to systematically escalate doses to find a balance between anti-tumor activity and patient tolerability. Specific findings regarding the MTD, observed toxicities, or pharmacokinetic data are not detailed in this abstract, which outlines the study's intent.